CD34 and leukemia: Taken together, these data confirm that overall alternative splicing of the c-myb gene was significantly elevated in leukemia samples compared to normal CD34+ cells, suggesting that alternative splicing of c-myb could provide a novel biomarker linked to prognosis or patient outcome.